Voyager Therapeutics
VYGR
98 hedge funds and large institutions have $418M invested in Voyager Therapeutics in 2017 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 37 increasing their positions, 16 reducing their positions, and 17 closing their positions.
135% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 17
131% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 16
80% more capital invested
Capital invested by funds: $233M → $418M (+$185M)
46% more call options, than puts
Call options by funds: $1.84M | Put options by funds: $1.26M
38.03% more ownership
Funds ownership: 42.06% → 80.08% (+38%)
31% more funds holding
Funds holding: 75 → 98 (+23)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$26.4M |
| 2 |
BlackRock
New York
|
+$8.82M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.35M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$7.94M |
| 5 |
Axa
Paris,
France
|
+$5.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.19M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.05M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.49M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$4.88M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.69M |
VYGR Hedge Fund Activity: Q4 2017 in Review
98 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2017, worth a combined $418M — up 80% from $233M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new VYGR positions and 17 closed out — a net gain of 23 holders — while 37 added to existing stakes and 16 trimmed.
The largest buyer was BB Biotech, opening a new position worth an estimated $26.4M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $8.19M sold.
- 98 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2017, up from 75 in Q3 2017.
- Funds reported $418M of Voyager Therapeutics stock for Q4 2017, up 80% quarter-over-quarter.
- 40 funds opened new Voyager Therapeutics positions in Q4 2017 and 17 closed out, a net change of +23 holders.
- The largest Voyager Therapeutics buyer in Q4 2017 was BB Biotech, an estimated $26.4M added.
- The largest Voyager Therapeutics seller in Q4 2017 was PFM Health Sciences, an estimated $8.19M sold.
Based on aggregated 13F filings for Q4 2017.